Severe Asthma Reference Guide Phenotypes, Endotypes, Biomarkers, and Treatment

Target Audience

A CME/CE-certified supplement to CHEST® Physician

This activity is intended for pulmonologists, family practitioners, internists, physician assistants, nurse practitioners, and other clinicians who treat patients with asthma.

Supported by educational grants from:

Sanofi Genzyme and Regeneron Pharmaceuticals

Activity Information

Original Release Date: October 1, 2018
Expiration Date: October 1, 2019
Estimated Time to Complete Activity: 2.0 hours
Media: Monograph

Faculty

Michael E. Wechsler, MD, MMSc
Professor of Medicine
Division of Pulmonary, Critical Care, and Sleep Medicine
Director, NJH Cohen Family Asthma Institute
National Jewish Health
Denver, Colorado

Amit D. Parulekar, MD, MS, FCCP
Associate Professor of Medicine
Section of Pulmonary, Critical Care, and Sleep Medicine
Baylor College of Medicine
Houston, Texas

Method of Participation

Participants should read the activity information, review the activity in its entirety, and complete the online post-test and evaluation. Upon completing this activity as designed and achieving a passing score on the post-test, you will be directed to a Web page that will allow you to receive your certificate of credit via e-mail or you may print it out at that time. The online post-test and evaluation can be accessed at: https://tinyurl.com/AsthmaGuide18. Inquiries may be directed to Global Academy for Medical Education at info@globalacademycme.com or (973) 290-8225 or Postgraduate Institute for Medicine at (720) 895-5357.

CME Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Chest Physicians (CHEST) and Global Academy for Medical Education. The American College of Chest Physicians is accredited by The ACCME to provide continuing education for physicians.
The American College of Chest Physicians designates this enduring activity for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Postgraduate Institute for Medicine and Global Academy for Medical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 2.0 contact hours. Designated for 1.0 of pharmacotherapy credit for Advanced Practice Nurses.

Maintenance of Certification (MOC) Statement

Successful completion of this CME activity enables the participant to earn up to 2 MOC points in The American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program.
Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion Information to ACCME for the purpose of granting ABIM MOC points.
Upon successful completion of this course, CHEST will submit your completion data to ABIM via ACCME's Program and Activity Reporting System (PARS) for MOC points.

Statement of Needs

About 5% to 15% of patients with asthma have severe or uncontrolled asthma and experience ongoing symptoms despite daily treatment with inhaled or systemic corticosteroids and supplemental medications such as long-acting β agonists. Patients with severe asthma account for much of the morbidity and mortality associated with asthma. Severe asthma is a heterogeneous disease. In the last decade, researchers have defined many of the biological mechanisms underlying severe asthma. More recently, new treatments, as well as biomarkers that can predict response to the new treatments, are contributing to the development of personalized therapy for patients with severe asthma.

Disclosure Declarations

Individuals in a position to control the content of this educational activity are required to disclose: 1) the existence of any relevant financial relationship with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients with the exemption of non-profit or government organizations and non-health care related companies, within the past 12 months; and 2) the identification of a commercial product/device that is unlabeled for use or an investigational use of a product/device not yet approved.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with ACCME-defined commercial interests related to the content of this CME activity:
Amit D. Parulekar, MD, MS, FCCP, has nothing to disclose.
Michael E. Wechsler, MD, MMSc, Consultant: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Sanofi Regeneron, Teva. Grant/Research Support: AstraZeneca and Teva.
American College of Chest Physicians (CHEST) Staff has nothing to disclose.
CME/CE Reviewer: Courtney R. Schadt, MD, has nothing to disclose.
The Postgraduate Institute for Medicine planners and managers have nothing to disclose.
Global Academy for Medical Education planners and managers have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

 

Copyright © 2018 by Global Academy for Medical Education, LLC, Frontline Medical Communications Inc.,  and  its  Licensors.  All  rights  reserved.  No  part  of  this  publication  may  be  reproduced  or transmitted in any form, by any means, without prior written permission of the Publisher. Global Academy for Medical Education, LLC, Global Education Group, and Frontline Medical Communications will  not  assume  responsibility  for  damages,  loss,  or  claims  of  any  kind  arising  from  or  related  to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein